{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T18:08:51Z","timestamp":1781806131434,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"am","delay-in-days":313,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ahj.2023.01.014","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T03:46:40Z","timestamp":1674186400000},"page":"168-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["\u03b2eta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial"],"prefix":"10.1016","volume":"258","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1901-2808","authenticated-orcid":false,"given":"Johanne","family":"Silvain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cayla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Range","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Puymirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Delarche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaelle","family":"Dumaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Slama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Payot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad E.","family":"Kasty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Aacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2023.01.014_bib0001","unstructured":"European Cardiovascular Disease Statistics 2017 http:\/\/www.ehnheart.org\/cvd-statistics.html."},{"key":"10.1016\/j.ahj.2023.01.014_bib0002","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/eurheartj\/ehp492","article-title":"Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries","volume":"31","author":"Widimsky","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2023.01.014_bib0003","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/00005650-200108000-00008","article-title":"Assessing the clinical and economic burden of coronary artery disease: 1986-1998","volume":"39","author":"Eisenstein","year":"2001","journal-title":"Med Care"},{"key":"10.1016\/j.ahj.2023.01.014_bib0004","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/ehn018","article-title":"INTERHEART investigators. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study","volume":"29","author":"Anand","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2023.01.014_bib0005","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1136\/bmj.e356","article-title":"25 years trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study","volume":"344","author":"Schmidt","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2023.01.014_bib0006","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40256-019-00338-4","article-title":"Do patients need lifelong beta-blockers after an uncomplicated myocardial infarction?","volume":"19","author":"Zeitouni","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ahj.2023.01.014_bib0007","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(05)67661-1","article-title":"Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2023.01.014_bib0008","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2023.01.014_bib0009","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the Management of Patients with non-ST-Elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2023.01.014_bib0010","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2023.01.014_bib0011","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1161\/CIRCULATIONAHA.117.030798","article-title":"Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015","volume":"136","author":"Puymirat","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2023.01.014_bib0012","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"Beta-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction","volume":"69","author":"Dondo","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2023.01.014_bib0013","doi-asserted-by":"crossref","first-page":"i4801","DOI":"10.1136\/bmj.i4801","article-title":"Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study","volume":"354","author":"Puymirat","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ahj.2023.01.014_bib0014","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCOUTCOMES.114.001073","article-title":"Beta-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial","volume":"7","author":"Bangalore","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2023.01.014_bib0015","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2023.01.014_bib0016","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with \u03b2-blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2023.01.014_bib0017","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/eurheartj\/ehaa1058","article-title":"Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study","volume":"42","author":"Holt","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2023.01.014_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.010159","article-title":"Left ventricular ejection fraction 1 year after acute myocardial infarction identifies the benefits of the long-term use of beta-blockers: analysis of data from the KAMIR-NIH registry","volume":"14","author":"Park","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2023.01.014_bib0019","doi-asserted-by":"crossref","unstructured":"Puymirat E, Riant E, Aissaoui N et\u00a0al. Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 2016;354:i4801.","DOI":"10.1136\/bmj.i4801"},{"key":"10.1016\/j.ahj.2023.01.014_bib0020","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/eurheartj\/ehaa376","article-title":"Long-term beta-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study","volume":"41","author":"Kim","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2023.01.014_bib0021","article-title":"Betablocker Prescription and Outcomes in Uncomplicated Acute Myocardial Infarction: Insight from the ePARIS registry","author":"Suc","year":"2022","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ahj.2023.01.014_bib0022","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/eurheartj\/ehi705","article-title":"Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction","volume":"27","author":"Gislason","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2023.01.014_bib0023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE Study Group EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"4","key":"10.1016\/j.ahj.2023.01.014_bib0024","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/2047487315585293","article-title":"Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: Data from the SWEDEHEART registry","volume":"23","author":"Hambraeus","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ahj.2023.01.014_bib0025","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/heartjnl-2014-306754","article-title":"Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction","volume":"101","author":"Shore","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2023.01.014_bib0026","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12872-016-0283-6","article-title":"Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction","volume":"16","author":"Halvorsen","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ahj.2023.01.014_bib0027","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ehf2.13079","article-title":"Adherence to beta-blockers and long-term risk of heart failure and mortality after a myocardial infarction","volume":"8","author":"Desta","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ahj.2023.01.014_bib0028","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s13063-020-4214-6","article-title":"Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial","volume":"21","author":"Kristensen","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.ahj.2023.01.014_bib0029","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2018.10.005","article-title":"BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study","volume":"208","author":"Munkhaugen","year":"2019","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2023.01.014_bib0031","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/ehjcvp\/pvab060","article-title":"for the REBOOT-CNIC investigators. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)","volume":"8","author":"Rossello","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870323000212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870323000212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:10:58Z","timestamp":1757571058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870323000212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":30,"alternative-id":["S0002870323000212"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2023.01.014","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b2eta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2023.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}